CEL-SCI Corporation (CVM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CEL-SCI Corporation ("CEL-SCI" or "the Company") (NYSE: CVM). The investigation concerns whether CEL-SCI and certain of its officers and/or directors have violated federal securities laws.
On June 28, 2021, CEL-SCI issued a press release announcing that the Phase 3 study for the Company’s Multikine (leukocyte interleukin) immunotherapy candidate missed its primary endpoint for primary (previously untreated) squamous cell carcinoma of the head and neck. On this news, CEL-SCI’s stock price fell $11.39 per share, or 45.41%, to close at $13.69 per share on June 28, 2021.
If you are aware of any facts relating to this investigation, or purchased CEL-SCI shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.